Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.70
+0.05501.51%
Volume:28.14K
Turnover:104.69K
Market Cap:373.20M
PE:-8.59
High:3.82
Open:3.64
Low:3.64
Close:3.64
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.45
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.68
PE(LYR):-7.62

Loading ...

Galectin Therapeutics Submits FDA Registrational Phase 3 Protocol for Belapectin in MASH Cirrhosis, Portal Hypertension

Reuters
·
Oct 06

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

GlobeNewswire
·
Oct 06

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 10

Galectin Shares Slip on Wider Second-Quarter Loss

Dow Jones
·
Aug 14

Galectin Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate

Benzinga Earnings
·
Aug 14

Galectin Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 14

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 14

Galectin Therapeutics Inc: Q2 Net Loss Per Share $0.14 - SEC Filing

THOMSON REUTERS
·
Aug 14

Galectin Therapeutics Q2 FY26 Net Loss Widens 21.17% to $9.11 Million

Reuters
·
Aug 14

Galectin Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

TIPRANKS
·
Aug 04

Galectin Therapeutics Eliminates $105.8 Million Debt in Chairman Note-to-Equity Conversion

Reuters
·
Aug 04

Galectin Chair Uihlein Receives 34,376,167 Shares in Debt-to-Equity Conversion

Reuters
·
Aug 04

Galectin Therapeutics CMO Jamil Khurram Disposes of 16,250 Common Shares for $83,284.5

Reuters
·
Jul 17

Galectin Therapeutics Posts Corporate Presentation Highlighting Belapectin Program for MASH Cirrhosis, Portal Hypertension

Reuters
·
Jul 14

Galectin Therapeutics CMO Jamil Khurram Disposes of Common Shares Worth $262,943

Reuters
·
Jul 01

Galectin Therapeutics CMO Jamil Khurram Disposes of 7,557 Common Shares Worth $23,728.98

Reuters
·
Jun 26

Galectin Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD)

TIPRANKS
·
Jun 24